Skip to main content
Top
Published in: Abdominal Radiology 2/2006

01-04-2006

Tumor angiogenesis: pathophysiology and implications for contrast-enhanced MRI and CT assessment

Authors: C. A. Cuenod, L. Fournier, D. Balvay, J.-M. Guinebretière

Published in: Abdominal Radiology | Issue 2/2006

Login to get access

Abstract

The process of tumor neoangiogenesis plays a central role in the growth and spread of tumors. It is currently a leading theme in oncology, and many new drugs targeting the tumor neoangiogenic process are under development. Expanding tumors become hypoxic and tumor cells express transcription factors, such as the hypoxia-inducible factor (HIF), which induce the release of proangiogenic growth factors such as vascular endothelial growth factors (VEGF) and transforming growth factors that promote the formation of new capillaries by recruiting, activating, and stimulating endothelial cells. Activated endothelial cells secrete matrix metalloproteases, which degrade the basement membrane and the extracellular matrix, and adhesion receptors such as integrins αvβ3, which allow their migration into the extracellular matrix toward the tumor cells. The newly grown vessels are immature and differ from normal capillaries. They are tortuous and irregular, resulting in poorly efficient perfusion, they are leaky (especially to macromolecules), and they are independent of the normal mechanisms of regulation of the capillary blood flow. Moreover, tumor microcirculation is heterogeneous. Evaluation of angiogenesis can be used as a prognostic marker to evaluate the aggressiveness of tumor and as a potential predictive marker of antiangiogenic treatment response. Histopathologic techniques of microvascular density indexes require invasive tissue sampling and need to be standardized. Hemodynamic characteristics of immature neovessels can be noninvasively assessed by dynamic contrast-enhanced magnetic resonance imaging or computed tomography. Tissue enhancement depends on arterial input function, kinetic of distribution of blood into the capillary bed, leakage across the capillary walls, and volume of the interstitial space. Pharmacodynamic models allow the evaluation of microvascular parameters of tissue blood flow, tissue blood volume, tissue interstitial volume, mean transit time, and permeability by surface of capillary wall. Methods based on dynamic contrast enhancement have been shown to correlate with conventional outcome methods such as histopathologic studies and survival. Radiologists must be convinced that, by using this emerging and promising approach, it is becoming possible to gain functional information during routine tumor imaging.
Literature
1.
go back to reference Folkman J (1990) What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82:4–6PubMed Folkman J (1990) What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82:4–6PubMed
2.
go back to reference Brasch R, Turetschek K (2000) MRI characterization of tumors and grading angiogenesis using macromolecular contrast media: status report. Eur J Radiol 34:148–155CrossRefPubMed Brasch R, Turetschek K (2000) MRI characterization of tumors and grading angiogenesis using macromolecular contrast media: status report. Eur J Radiol 34:148–155CrossRefPubMed
3.
go back to reference Griebel J, Mayr NA, de Vries A, et al. (1997) Assessment of tumor microcirculation: a new role of dynamic contrast MR imaging. J Magn Reson Imaging 7:111–119PubMed Griebel J, Mayr NA, de Vries A, et al. (1997) Assessment of tumor microcirculation: a new role of dynamic contrast MR imaging. J Magn Reson Imaging 7:111–119PubMed
4.
go back to reference Neeman M (2000) Preclinical MRI experience in imaging angiogenesis. Cancer Metastasis Rev 19:39–43CrossRefPubMed Neeman M (2000) Preclinical MRI experience in imaging angiogenesis. Cancer Metastasis Rev 19:39–43CrossRefPubMed
5.
go back to reference Buckley DL, Roberts C, Parker GJ, et al. (2004) Prostate cancer: evaluation of vascular characteristics with dynamic contrast-enhanced T1-weighted MR imaging—initial experience. Radiology 233:709–715PubMed Buckley DL, Roberts C, Parker GJ, et al. (2004) Prostate cancer: evaluation of vascular characteristics with dynamic contrast-enhanced T1-weighted MR imaging—initial experience. Radiology 233:709–715PubMed
7.
go back to reference Lee TY, Purdie TG, Stewart E (2003) CT imaging of angiogenesis. Q J Nucl Med 47:171–187PubMed Lee TY, Purdie TG, Stewart E (2003) CT imaging of angiogenesis. Q J Nucl Med 47:171–187PubMed
8.
go back to reference Cuenod C, Leconte I, Siauve N, et al. (2001) Early changes in liver perfusion caused by occult metastases in rats: detection with quantitative CT. Radiology 218:556–561PubMed Cuenod C, Leconte I, Siauve N, et al. (2001) Early changes in liver perfusion caused by occult metastases in rats: detection with quantitative CT. Radiology 218:556–561PubMed
9.
go back to reference Ribatti D, Vacca A, Dammacco F (2003) New non-angiogenesis dependent pathways for tumor growth. Eur J Cancer 39:1835–1841PubMed Ribatti D, Vacca A, Dammacco F (2003) New non-angiogenesis dependent pathways for tumor growth. Eur J Cancer 39:1835–1841PubMed
10.
go back to reference Barentsz JO, Berger-Hartog O, Witjes JA, et al. (1998) Evaluation of chemotherapy in advanced urinary bladder cancer with fast dynamic contrast-enhanced MR imaging. Radiology 207:791–797PubMed Barentsz JO, Berger-Hartog O, Witjes JA, et al. (1998) Evaluation of chemotherapy in advanced urinary bladder cancer with fast dynamic contrast-enhanced MR imaging. Radiology 207:791–797PubMed
11.
12.
go back to reference Anderson H, Price P, Blomley M, et al. (2001) for the Cancer Research Campaign PK/PD Technologies Advisory Committee. Measuring changes in human tumour vasculature in response to therapy using functional imaging techniques. Br J Cancer 85:1085–1093PubMed Anderson H, Price P, Blomley M, et al. (2001) for the Cancer Research Campaign PK/PD Technologies Advisory Committee. Measuring changes in human tumour vasculature in response to therapy using functional imaging techniques. Br J Cancer 85:1085–1093PubMed
13.
go back to reference Pradel C, Siauve N, Bruneteau G, et al. (2003) Reduced capillary perfusion and permeability in human tumour xenografts treated with the VEGF signalling inhibitor ZD4190: an in vivo assessment using dynamic MR imaging and macromolecular contrast media. Magn Reson Imaging 21:845–851PubMed Pradel C, Siauve N, Bruneteau G, et al. (2003) Reduced capillary perfusion and permeability in human tumour xenografts treated with the VEGF signalling inhibitor ZD4190: an in vivo assessment using dynamic MR imaging and macromolecular contrast media. Magn Reson Imaging 21:845–851PubMed
14.
go back to reference Ribatti D, Vacca A, Dammacco F (2003) New non-angiogenesis dependent pathways for tumor growth. Eur J Cancer 39:1835–1841PubMed Ribatti D, Vacca A, Dammacco F (2003) New non-angiogenesis dependent pathways for tumor growth. Eur J Cancer 39:1835–1841PubMed
15.
go back to reference Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285:1182–1186PubMed Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285:1182–1186PubMed
16.
go back to reference Brahimi-Horn MC, Pouyssegur J (2005) The hypoxia-inducible factor and tumor progression along the angiogenic pathway. Int Rev Cytol 242:157–213PubMed Brahimi-Horn MC, Pouyssegur J (2005) The hypoxia-inducible factor and tumor progression along the angiogenic pathway. Int Rev Cytol 242:157–213PubMed
17.
go back to reference Latif F, Tory K, Gnarra J, et al. (1993) Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 260:1317–1320PubMed Latif F, Tory K, Gnarra J, et al. (1993) Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 260:1317–1320PubMed
18.
go back to reference Haas TL, Madri JA (1999) Extracellular matrix-driven matrix metalloproteinase production in endothelial cells: implications for angiogenesis. Trends Cardiovasc Med 9:70–77CrossRefPubMed Haas TL, Madri JA (1999) Extracellular matrix-driven matrix metalloproteinase production in endothelial cells: implications for angiogenesis. Trends Cardiovasc Med 9:70–77CrossRefPubMed
19.
go back to reference Liotta LA, Steeg PS, Stetler-Scevenson WG (1991) Cancer metastasis and angiogenesis; An imbalance of positive and negative regulation. Cell 64:327–336CrossRefPubMed Liotta LA, Steeg PS, Stetler-Scevenson WG (1991) Cancer metastasis and angiogenesis; An imbalance of positive and negative regulation. Cell 64:327–336CrossRefPubMed
20.
go back to reference Hwang R, Varner J (2004) The role of integrins in tumor angiogenesis. Hematol Oncol Clin North Am 18:991–1006,CrossRefPubMed Hwang R, Varner J (2004) The role of integrins in tumor angiogenesis. Hematol Oncol Clin North Am 18:991–1006,CrossRefPubMed
21.
go back to reference Brooks PC, Dark. RA, Cheresh DA (1994) Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 264:569–571PubMed Brooks PC, Dark. RA, Cheresh DA (1994) Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 264:569–571PubMed
22.
go back to reference Ribatti D (2004) The involvement of endothelial progenitor cells in tumor angiogenesis. J Cell Mol Med 8:294–300PubMed Ribatti D (2004) The involvement of endothelial progenitor cells in tumor angiogenesis. J Cell Mol Med 8:294–300PubMed
23.
go back to reference Anderson SA, Glod J, Arbab AS, et al. (2005) Noninvasive MR imaging of magnetically labeled stem cells to directly identify neovasculature in a glioma model. Blood 105:420–425PubMed Anderson SA, Glod J, Arbab AS, et al. (2005) Noninvasive MR imaging of magnetically labeled stem cells to directly identify neovasculature in a glioma model. Blood 105:420–425PubMed
24.
go back to reference Jain RK (1988) Determinants of tumor blood flow: a review. Cancer Res 15:2641–2658 Jain RK (1988) Determinants of tumor blood flow: a review. Cancer Res 15:2641–2658
25.
go back to reference Less JR, Posner MC, Skalak TC, et al. (1997) Geometric resistance and microvascular network architecture of human colorectal carcinoma. Microcirculation 4:25–33PubMed Less JR, Posner MC, Skalak TC, et al. (1997) Geometric resistance and microvascular network architecture of human colorectal carcinoma. Microcirculation 4:25–33PubMed
26.
go back to reference Jain RK (1996) Delivery of molecular medicine to solid tumors. Science 271:1079–1080PubMed Jain RK (1996) Delivery of molecular medicine to solid tumors. Science 271:1079–1080PubMed
27.
go back to reference Less JR, Skalak TC, Sevick EM, Jain RK (1991) Microvascular architecture in a mammary carcinoma: branching patterns and vessel dimensions. Cancer Res 51:265–273PubMed Less JR, Skalak TC, Sevick EM, Jain RK (1991) Microvascular architecture in a mammary carcinoma: branching patterns and vessel dimensions. Cancer Res 51:265–273PubMed
28.
go back to reference Liotta LA, Kleinennan J, Saidel GM (1974) Quantitative relationships of intravascular tumor cells, tumor vessels, and pulmonary metastases following tumor implantation. Cancer Res 34:997–1004PubMed Liotta LA, Kleinennan J, Saidel GM (1974) Quantitative relationships of intravascular tumor cells, tumor vessels, and pulmonary metastases following tumor implantation. Cancer Res 34:997–1004PubMed
29.
go back to reference Dvorak HF, Nagy JA, Dvorak JT, et al. (1988) Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. Am J Pathol 133:95–109PubMed Dvorak HF, Nagy JA, Dvorak JT, et al. (1988) Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. Am J Pathol 133:95–109PubMed
30.
go back to reference Gasparini G, Weidner N, Bevilacqua P, et al. (1994) Tumor microvessel density, p53 expression, tumor size, and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma. J Clin Oncol 12:454–466PubMed Gasparini G, Weidner N, Bevilacqua P, et al. (1994) Tumor microvessel density, p53 expression, tumor size, and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma. J Clin Oncol 12:454–466PubMed
31.
go back to reference Miller JC, Pien HH, Sahani D, et al. (2005) Imaging angiogenesis: applications and potential for drug development. J Natl Cancer Inst 97:172–187PubMed Miller JC, Pien HH, Sahani D, et al. (2005) Imaging angiogenesis: applications and potential for drug development. J Natl Cancer Inst 97:172–187PubMed
32.
33.
go back to reference McDonald DM, Choyke PL (2003) Imaging of angiogenesis: from microscope to clinic. Nat Med 9:713–725CrossRefPubMed McDonald DM, Choyke PL (2003) Imaging of angiogenesis: from microscope to clinic. Nat Med 9:713–725CrossRefPubMed
34.
go back to reference Tofts PS, Brix G, Buckley DL (1999) Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 10:223–232CrossRefPubMed Tofts PS, Brix G, Buckley DL (1999) Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 10:223–232CrossRefPubMed
35.
go back to reference Buckley DL (2002) Uncertainty in the analysis of tracer kinetics using dynamic contrast-enhanced T1-weighted MRI. Magn Reson Med 47:601–606PubMed Buckley DL (2002) Uncertainty in the analysis of tracer kinetics using dynamic contrast-enhanced T1-weighted MRI. Magn Reson Med 47:601–606PubMed
36.
go back to reference Evelhoch JL (1999) Key factors in the acquisition of contrast kinetic data for oncology. J Magn Reson Imaging 10:254–259CrossRefPubMed Evelhoch JL (1999) Key factors in the acquisition of contrast kinetic data for oncology. J Magn Reson Imaging 10:254–259CrossRefPubMed
37.
go back to reference Padhani AR, Neeman M (2001) Challenges for imaging angiogenesis. Br J Radiol 74:886–890PubMed Padhani AR, Neeman M (2001) Challenges for imaging angiogenesis. Br J Radiol 74:886–890PubMed
Metadata
Title
Tumor angiogenesis: pathophysiology and implications for contrast-enhanced MRI and CT assessment
Authors
C. A. Cuenod
L. Fournier
D. Balvay
J.-M. Guinebretière
Publication date
01-04-2006
Publisher
Springer-Verlag
Published in
Abdominal Radiology / Issue 2/2006
Print ISSN: 2366-004X
Electronic ISSN: 2366-0058
DOI
https://doi.org/10.1007/s00261-005-0386-5

Other articles of this Issue 2/2006

Abdominal Radiology 2/2006 Go to the issue

OriginalPaper

Author’s reply

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.